Bone metastases in prostate cancer – Gallium-68–labeled prostate-specific membrane antigen or Fluorine 18 sodium fluoride PET/computed tomography – the better tracer?
Archi Agrawal(Tata Memorial Hospital), Venkatesh Rangarajan(Tata Memorial Hospital), Ameya Puranik(Homi Bhabha National Institute), Gagan Prakash(Homi Bhabha National Institute), Mahendra Pal(Bihar Agricultural University), Priyamvada Maitre(Homi Bhabha National Institute), Vedang Murthy(Homi Bhabha National Institute), Ganesh Bakshi(P. D. Hinduja Hospital and Medical Research Centre), Sayak Choudhury(Society of Nuclear Medicine and Molecular Imaging), Vanita Noronha(Homi Bhabha National Institute), Amit Joshi(Dr. Rajendra Prasad Government Medical College), Santosh Menon(Homi Bhabha National Institute), Kumar Prabhash(Homi Bhabha National Institute), Sneha Mithun(Society of Nuclear Medicine and Molecular Imaging), Sneha Shah(Tata Memorial Hospital), Nilendu Purandare(Tata Memorial Hospital), Aravintho Natarajan(Tata Memorial Hospital)
Cited by 11
Related Papers
The Lancet Commission on prostate cancer: planning for the surge in cases
|The Lancet|2024|694
Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017
|European Urology|2017|644
Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019
|European Urology|2020|396
Diagnostic performance of post-treatment FDG PET or FDG PET/CT imaging in head and neck cancer: a systematic review and meta-analysis
|European Journal of Nuclear Medicine and Molecular Imaging|2011|377
Once-a-Week Versus Once-Every-3-Weeks Cisplatin Chemoradiation for Locally Advanced Head and Neck Cancer: A Phase III Randomized Noninferiority Trial
|Journal of Clinical Oncology|2017|340